When a company’s stock gets delisted and the ticker changes overnight, it looks alarming. Social media fills up with panic, investors start searching for answers, and the phrase “going out of business” starts trending. But here’s the thing — a stock delisting is not the same as a company shutting down.
This article gives you a straight answer on whether Zomedica is closing, explains what the NYSE American delisting actually was, and breaks down what trading on OTCQB means for shareholders going forward.
The Short Answer — Zomedica Is Not Confirmed to Be Closing
As of the available information, Zomedica has not filed for bankruptcy, issued a liquidation notice, or announced that it is ceasing operations. The company stated it would continue running its business and keep filing the required reports with the SEC even after the delisting.
The confusion comes from one specific event: NYSE American began delisting proceedings against Zomedica in March 2025. That event is real and significant — but it is a stock exchange compliance issue, not a shutdown announcement.
If you came here wondering whether Zomedica has turned off the lights, the honest answer based on available information is no. But there is important context worth understanding before you make any decisions as an investor or business observer.
Why Zomedica Was Delisted From NYSE American
NYSE American removed Zomedica because the company’s share price fell below the exchange’s minimum price standard and stayed there. That’s it. No fraud, no court order, no insolvency declaration.
Every major stock exchange sets its own listing standards. These rules cover things like minimum share price, market capitalization, and financial reporting requirements. When a company consistently fails to meet those standards, the exchange starts a formal delisting process.
For Zomedica, the issue was share price. The stock had dropped and stayed below the threshold NYSE American requires. The exchange is not in the business of keeping struggling stocks on its platform — once the threshold is breached and not corrected, delisting follows.
This process began in March 2025. It does not mean a court found Zomedica insolvent. It does not mean regulators shut the company down. It means the stock no longer qualifies to trade on that particular exchange.
What OTCQB Is and Where Zomedica Trades Now
After the delisting, Zomedica’s shares moved to the OTCQB Venture Market. Trading began there under the ticker ZOMDF, effective March 5, 2025.
If you held shares under the old ticker ZOM, you are looking at the same company. The ticker changed because the trading venue changed. There was no corporate restructuring, no name change, and no new company created.
OTCQB is a legitimate over-the-counter market that many smaller public companies use. It is regulated and requires companies to stay current with their SEC filings. It is not a junkyard for failed businesses — it is simply a different tier of the public markets.
That said, there are real practical differences. Stocks on OTCQB generally have lower trading volume and less visibility than those listed on NYSE or Nasdaq. Buying and selling shares can be harder, spreads can be wider, and institutional investors often avoid OTC markets. These are real concerns for shareholders, but they describe trading conditions — not whether the company is selling products or paying its employees.
A simple way to think about it: imagine a retailer moving from a major mall to a smaller shopping center. The location is less prominent, foot traffic drops, and visibility shrinks. But the store is still open, staff are still working, and products are still on the shelves. The venue changed. The business didn’t close.
Delisting, Bankruptcy, and Going Out of Business Are Not the Same Thing
This is where a lot of investors and observers get confused, so it is worth being very clear.
Delisting
Delisting means a company no longer meets a stock exchange’s listing requirements and gets removed from that exchange. The company itself keeps existing. It can still operate, sell products, hire people, and file SEC reports. The stock just trades somewhere else — or in some cases, not at all.
Bankruptcy
Bankruptcy is a legal process. Chapter 7 means a company is being liquidated — assets are sold to pay creditors, and the business shuts down. Chapter 11 means the company is reorganizing its finances under court protection, trying to survive. Neither type has been filed by Zomedica based on available information.
Going Out of Business
Going out of business means the company stops serving customers, stops selling products, and shuts down operations. This requires an actual announcement or observable evidence — closed facilities, terminated employees, products pulled from the market. None of that has been confirmed for Zomedica.
A company can have a very low share price, lose its exchange listing, and still run a functioning business. These things feel connected, but legally and operationally, they are separate.
Losing an NYSE listing is a setback and a warning sign. But it is not the same as turning off the lights.
What Zomedica’s Business Actually Does
Zomedica describes itself as a veterinary-health company. Its focus is on diagnostic and therapeutic products for companion animals — think dogs and cats, not livestock.
After the delisting, the company stated it would continue its diagnostic and therapeutic product programs. It also confirmed it would keep meeting its SEC reporting obligations, which means it remains a public reporting company even while trading on OTCQB.
The veterinary diagnostics space is a real market with real customers — veterinary practices that use tools to test and treat animals. Whether Zomedica’s specific products are gaining traction, losing market share, or facing competitive pressure is a separate question that requires looking at its financial filings directly. But the business category itself is not trivial or fictional.
For anyone evaluating whether this company has a viable future, the stock delisting is one data point — not the whole picture. You would also want to look at revenue trends, cash on hand, product adoption rates, and management commentary in recent quarterly filings.
What This Means for Shareholders Practically
If you currently hold Zomedica shares, here is what actually changed and what did not.
- Your shares still exist. The ZOMDF ticker represents the same ownership stake you had under ZOM. Nothing was erased.
- Trading is harder. OTCQB has lower liquidity. Selling a large position may be more difficult than it was on NYSE American.
- The company still reports to the SEC. You can still access quarterly and annual filings to see how the business is performing.
- A return to a major exchange is possible but not guaranteed. Companies can relist if they meet the requirements again — often through a reverse stock split to raise the share price. Zomedica has not announced a confirmed path back as of the available information.
- Institutional interest may drop. Many funds cannot hold OTC stocks by policy. That can reduce demand for the shares and put additional pressure on the price.
None of these points mean the company is done. They mean the investment environment has changed, and shareholders should go in with clear eyes.
How to Track What Actually Happens Next
If you want to stay informed on Zomedica’s actual status, skip social media speculation and go directly to primary sources.
Check the SEC’s EDGAR database for the company’s most recent 10-Q and 10-K filings. These documents show real revenue, cash position, and management commentary on the business outlook. If the company were approaching insolvency, you would typically see warning language in these filings — what accountants call a “going concern” qualification.
Also watch for any press releases from Zomedica’s investor relations team regarding financing, product updates, or strategic changes. Companies in transition often announce reverse splits, new partnerships, or capital raises that can change the picture quickly.
For broader context on how to evaluate small-cap and OTC-listed companies, resources like Start Business Review cover business fundamentals that apply whether a company is listed on a major exchange or trading over the counter.
Bottom Line
Zomedica is not confirmed to be going out of business. The company was delisted from NYSE American in March 2025 due to a share price compliance issue — not bankruptcy, not fraud, not a shutdown order.
Its shares now trade on the OTCQB Venture Market under the ticker ZOMDF. The company stated it would continue operations and keep filing with the SEC. That is the factual situation based on available information.
Whether Zomedica recovers, stays in its current state, or eventually fails is genuinely uncertain. Small companies with low share prices and OTC listings face real challenges. But uncertainty is not the same as confirmation of failure.
If you are an investor or someone following this company, base your decisions on SEC filings and official announcements — not on the panic that typically surrounds a delisting notice. The two things most commonly confused in situations like this are “the stock is in trouble” and “the business is done.” Those are very different statements, and right now, only the first one is clearly supported by the evidence.
Read Also:
